论文部分内容阅读
重组的组织型纤溶酶原激活剂(rt-PA)作溶栓剂广泛用于治疗急性心梗(AMI)。rt-PA 静注10mg 可使大约71%的闭塞冠状动脉在治后90min 再通。与对照组相比,该药改善了心室功能,提高了患者的存活率。与链激酶和尿激酶的一个不同点是 rt-PA 对纤维蛋白相对特异,这样就会减少循环中游离的纤溶酶原活化成纤溶酶。结果,在引起冠脉再通的同等速率剂量下,rt-PA 可使纤维蛋白原,第Ⅴ和Ⅶ因子的降低程度减小,尽管 rt-PA 具有这种理论上的优
Recombinant tissue plasminogen activator (rt-PA) as a thrombolytic agent is widely used to treat acute myocardial infarction (AMI). Approximately 71% of the occluded coronary arteries were recanalized at 90 minutes after rt-PA was administered at 10 mg. Compared with the control group, the drug improves ventricular function and improves patient survival. One difference from streptokinase and urokinase is that rt-PA is relatively specific to fibrin, which reduces the activation of free plasminogen in the circulation to plasmin. As a result, rt-PA reduced the decrease in fibrinogen, factor V and factor VII at the same rate of coronary recanalization, although rt-PA possessed this theoretical superiority